Bluetongue virus with mutated genome segment 10 to differentiate infected from vaccinated animals: A genetic DIVA approach

P.A. van Rijn, S.G.P. van de Water, H.G.P. van Gennip

Research output: Contribution to journalArticleAcademicpeer-review

16 Citations (Scopus)

Abstract

Bluetongue virus (BTV) includes 24 serotypes and recently even more serotypes are proposed. Mass vaccination campaigns highlight the need for differential diagnostics in vaccinated populations. Bluetongue disease is routinely diagnosed by serological and virological tests by which differentiation infected from vaccinated animals (DIVA principle) is not possible. Real time PCR tests preferably detect all BTV serotypes (panBTV PCR tests). These PCR tests operate as frontline test to detect new BTV incursions. However, highly sensitive panBTV PCR tests can also detect currently applied inactivated and modified-live vaccines. Here, BTV with eight silent mutations in segment 10 (Seg-10) was generated by reverse genetics. This BTV mutant is not detected by a Seg-10 panBTV PCR test (genetic DIVA). Thus, inactivated BT vaccine with this mutated Seg-10 will avoid false positive PCR results post vaccination, whereas BTV infected animals can be positively diagnosed with the accompanying Seg-10 panBTV PCR test (DIVA-test) far beyond the infectious period.
Original languageEnglish
Pages (from-to)5005-5008
JournalVaccine
Volume31
Issue number44
DOIs
Publication statusPublished - 2013

Fingerprint

Bluetongue virus
Genome
Polymerase Chain Reaction
genome
animals
testing
serotypes
Bluetongue
Mass Vaccination
Reverse Genetics
Immunization Programs
Inactivated Vaccines
Serologic Tests
vaccination
Real-Time Polymerase Chain Reaction
Vaccination
bluetongue
Vaccines
inactivated vaccines
live vaccines

Keywords

  • polymerase-chain-reaction
  • serotype
  • assay

Cite this

@article{0052d61298cc478e816c7c0d815d89e6,
title = "Bluetongue virus with mutated genome segment 10 to differentiate infected from vaccinated animals: A genetic DIVA approach",
abstract = "Bluetongue virus (BTV) includes 24 serotypes and recently even more serotypes are proposed. Mass vaccination campaigns highlight the need for differential diagnostics in vaccinated populations. Bluetongue disease is routinely diagnosed by serological and virological tests by which differentiation infected from vaccinated animals (DIVA principle) is not possible. Real time PCR tests preferably detect all BTV serotypes (panBTV PCR tests). These PCR tests operate as frontline test to detect new BTV incursions. However, highly sensitive panBTV PCR tests can also detect currently applied inactivated and modified-live vaccines. Here, BTV with eight silent mutations in segment 10 (Seg-10) was generated by reverse genetics. This BTV mutant is not detected by a Seg-10 panBTV PCR test (genetic DIVA). Thus, inactivated BT vaccine with this mutated Seg-10 will avoid false positive PCR results post vaccination, whereas BTV infected animals can be positively diagnosed with the accompanying Seg-10 panBTV PCR test (DIVA-test) far beyond the infectious period.",
keywords = "polymerase-chain-reaction, serotype, assay",
author = "{van Rijn}, P.A. and {van de Water}, S.G.P. and {van Gennip}, H.G.P.",
year = "2013",
doi = "10.1016/j.vaccine.2013.08.089",
language = "English",
volume = "31",
pages = "5005--5008",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier",
number = "44",

}

Bluetongue virus with mutated genome segment 10 to differentiate infected from vaccinated animals: A genetic DIVA approach. / van Rijn, P.A.; van de Water, S.G.P.; van Gennip, H.G.P.

In: Vaccine, Vol. 31, No. 44, 2013, p. 5005-5008.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Bluetongue virus with mutated genome segment 10 to differentiate infected from vaccinated animals: A genetic DIVA approach

AU - van Rijn, P.A.

AU - van de Water, S.G.P.

AU - van Gennip, H.G.P.

PY - 2013

Y1 - 2013

N2 - Bluetongue virus (BTV) includes 24 serotypes and recently even more serotypes are proposed. Mass vaccination campaigns highlight the need for differential diagnostics in vaccinated populations. Bluetongue disease is routinely diagnosed by serological and virological tests by which differentiation infected from vaccinated animals (DIVA principle) is not possible. Real time PCR tests preferably detect all BTV serotypes (panBTV PCR tests). These PCR tests operate as frontline test to detect new BTV incursions. However, highly sensitive panBTV PCR tests can also detect currently applied inactivated and modified-live vaccines. Here, BTV with eight silent mutations in segment 10 (Seg-10) was generated by reverse genetics. This BTV mutant is not detected by a Seg-10 panBTV PCR test (genetic DIVA). Thus, inactivated BT vaccine with this mutated Seg-10 will avoid false positive PCR results post vaccination, whereas BTV infected animals can be positively diagnosed with the accompanying Seg-10 panBTV PCR test (DIVA-test) far beyond the infectious period.

AB - Bluetongue virus (BTV) includes 24 serotypes and recently even more serotypes are proposed. Mass vaccination campaigns highlight the need for differential diagnostics in vaccinated populations. Bluetongue disease is routinely diagnosed by serological and virological tests by which differentiation infected from vaccinated animals (DIVA principle) is not possible. Real time PCR tests preferably detect all BTV serotypes (panBTV PCR tests). These PCR tests operate as frontline test to detect new BTV incursions. However, highly sensitive panBTV PCR tests can also detect currently applied inactivated and modified-live vaccines. Here, BTV with eight silent mutations in segment 10 (Seg-10) was generated by reverse genetics. This BTV mutant is not detected by a Seg-10 panBTV PCR test (genetic DIVA). Thus, inactivated BT vaccine with this mutated Seg-10 will avoid false positive PCR results post vaccination, whereas BTV infected animals can be positively diagnosed with the accompanying Seg-10 panBTV PCR test (DIVA-test) far beyond the infectious period.

KW - polymerase-chain-reaction

KW - serotype

KW - assay

U2 - 10.1016/j.vaccine.2013.08.089

DO - 10.1016/j.vaccine.2013.08.089

M3 - Article

VL - 31

SP - 5005

EP - 5008

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 44

ER -